Concurrently, CREB1 inhibitors (666‐15) have been tested preclinically that inhibited CREB1 activity by disrupting its interaction with coactivators, showing efficacy in models of osteoarthritis and viral infections [42]. Here, CREB1 is linked to viral infectious disease.